Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 17/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.48 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125673 | 0.93 | PIK3CB (0.53) | PIK3CBPIK3CDPIK3CAPIK3CGNAPEPLD | |
| SCHEMBL10125140 | 0.92 | PDCD1 (0.49) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL10125144 | 0.92 | PDCD1 (0.49) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL16308169 | 0.91 | PIK3CB (0.41) | PIK3CBPIK3CDPIK3CAPIK3CGNAPEPLD | |
| SCHEMBL16308168 | 0.91 | PIK3CB (0.41) | PIK3CBPIK3CDPIK3CAPIK3CGNAPEPLD | |
| SCHEMBL10124715 | 0.91 | PIK3CB (0.41) | PIK3CBPIK3CDPIK3CAPIK3CGNAPEPLD | |
| SCHEMBL10124714 | 0.91 | PIK3CB (0.41) | PIK3CBPIK3CDPIK3CAPIK3CGNAPEPLD | |
| SCHEMBL10124531 | 0.91 | PIK3CD (0.58) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL10125150 | 0.91 | PIK3CB (0.45) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL10124911 | 0.91 | PIK3CB (0.42) | PIK3CBPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912180-B2 | Heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2014-12-16 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PIK3CB 13/4885PIK3CD 7/4885PIK3CA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.